Q-omics provides the consensus-scored CTF2P profile across patient tissues and cancer cell-line models. CTF2P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, CTF2P is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, CTF2P RNA expression shows 10,798 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CHOL, and TGCT as cancer lineages where CTF2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTF2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTF2P survival associations across molecular data types. CTF2P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTF2P RNA expression–survival associations across cancer types. High CTF2P expression shows unfavorable associations in CHOL, LGG, SKCM and READ, but favorable associations in ACC and LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for CTF2P RNA expression.
This table summarizes CTF2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for CTF2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTF2P shows lower tumor expression in ESCA and STAD and higher tumor expression in CHOL. The CHOL box plot shows higher CTF2P RNA expression in tumor versus normal tissue (log2 FC = +0.305, t-test p < 0.001).
This table shows molecular features associated with CTF2P in patient tissues and cancer cell lines. In patient samples, CTF2P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
